Cytomed Therapeutics Ltd income statement

In fiscal 2025, Cytomed Therapeutics Ltd reported revenue of $248,384, up 377.5% on the year before and net income of −$3.0m, or −$0.26 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cytomed Therapeutics Ltd: income statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025
Revenue	52	248
Research and development	1,429	1,698
Interest expense	15	16
Income before tax	−1,888	−3,060
Net income	−1,884	−3,048
Diluted EPS	−$0.16	−$0.26
Diluted shares (average)	12m	12m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CLNN vs GDTC CRVO vs GDTC CLDX vs GDTC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cytomed Therapeutics Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cytomed Therapeutics Ltd.